We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Molecular Test Effectively Guides Extent of Initial Thyroidectomy

By LabMedica International staff writers
Posted on 05 Aug 2014
The routine use of a molecular testing panel increases the likelihood of performing the correct initial surgery for patients with thyroid nodules and cancer.

A clinical algorithm using routine cytological molecular testing (MT) promotes initial total thyroidectomy (TT) for clinically significant thyroid cancer (sTC) and/or correctly limits surgery to lobectomy when appropriate. More...
Either TT or lobectomy is often needed to diagnose differentiated thyroid cancer and determining the correct extent of initial thyroidectomy is challenging.

Scientists at the University of Pittsburgh Medical Center (Pittsburgh, PA, USA) conducted a single-institution cohort study of 671 patients with nonmalignant cytology who had thyroidectomy between October 2010 and March 2012. Cytological diagnosis was made using the 2008 Bethesda criteria, and one or more indications for thyroidectomy. The patients who received biopsies all had suspicious thyroid nodes.

Approximately half the biopsy samples were run through the molecular panel, and the other half were not. Patients whose tissue samples were not tested with the panel had a 2.5-fold higher statistically significant likelihood of having an initial lobectomy and then requiring a second operation. Using a routine algorithm for prospective MT, the team demonstrated that the likelihood of optimal initial thyroid surgery is increased by the reflexive use of testing a molecular marker panel of proto-oncogene B-Raf (BRAF), Rat sarcoma (RAS), Paired box gene 8- peroxisome proliferator-activated receptor γ 1 (PAX8-PPARγ), and Rearranged in Transformation/Papillary Thyroid Carcinomas (RET-PTC) on fine needle aspiration biopsy (FNAB) specimens.

By analyzing new data from a single institution that has been prospectively and routinely using FNAB-MT since 2007, the investigators observed that, overall, FNAB-MT facilitated a 30% increase in the appropriate use of initial TT for sTC histology and a 33% increase in the appropriate use of initial lobectomy for non-sTC histology. Yuri Nikiforov, MD, PhD, a professor of pathology and coauthor of the study said, “We're currently refining the panel by adding tests for more genetic mutations, thereby making it even more accurate. Thyroid cancer is usually very curable, and we are getting closer to quickly and efficiently identifying and treating all cases of thyroid cancer.” The study was published in July 2014 issue of the Annals of Surgery.

Related Links:

University of Pittsburgh Medical Center



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Quality Control Material
Multichem ID-B
New
Host Response Immunoassay Test
MeMed BV
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.